CD274 and chronic obstructive pulmonary disease: Similarly, several studies have suggested that patients with advanced-stage LC and concurrent COPD, when treated with anti-PD-1/PD-L1 therapies, might have greater benefits from these agents in terms of overall survival (OS), PFS, and ORR while also improving the clinical and functional outcomes of COPD—including FEV1 and FVC.